黄欣昊;柳千帆;宋春灼;朱海涛;
HUANG Xinhao;LIU Qianfan;SONG Chunzuo;ZHU Haitao;Department of Clinical Medicine, Guizhou Medical University;Clinical Research Center of the Affiliated Hospital of Guizhou Medical University;Department of Hepatobiliary Surgery, The Affiliated Hospital of Guizhou Medical University;

• 1:贵州医科大学临床医学院
• 2:贵州医科大学附院临床研究中心
• 3:贵州医科大学
• 4:贵州医科大学附院肝胆外科

摘要(Abstract)：

目的:探讨吉西他滨(GEM)联合厄洛替尼(ERL)通过抑制突变型p53蛋白表达促进胰腺癌细胞凋亡的分子机制。方法:选用人胰腺癌细胞株PANC-1对数生长期细胞,将细胞分为对照组(无处理)、ERL组(ERL干预浓度12 nmol/L)、GEM组(GEM干预浓度80 nmol/L)、ERL联合GEM组(联合组,GEM干预浓度为4 nmol/L,ERL干预浓度为20 nmol/L),采用Annexin-V APC/7AAD法检测各组细胞的凋亡,采用实时荧光定量PCR检测各组细胞p53基因表达,采用Western blot法检测各组细胞p53蛋白和B淋巴细胞瘤-2相关蛋白X(BAX)的表达量。结果:联合组PANC-1细胞的凋亡率高于对照组、GEM组及ERL组(P<0.05或P<0.01);与对照组比较,GEM组、ERL组和联合组PANC-1细胞中p53基因的表达量均明显下降(P<0.001);联合组PANC-1细胞中p53蛋白表达量分别低于对照组、GEM组和ERL组(P<0.05或P<0.01),但BAX蛋白表达量分别高于对照组、GEM组和ERL组(P<0.05或P<0.01)。结论:GEM联合ERL可能下调突变型p53,诱导并上调BAX的表达,从而发挥促进肿瘤凋亡的作用。
Objective: To investigate the effect of Gemcitabine(GEM) combined with Erlotinib(ERL) on the apoptosis of human pancreatic cancer cells and its possible molecular mechanism. Methods: Human pancreatic cancer cells in logarithmic growth phase(PANC-1) were selected and divided into the control group(without treatment), ERL group(ERL intervention concentration 12 nmol/L), and GEM group(GEM intervention concentration 80 nmol/L), GEM and ERL group(combined group with 4 nmol/L GEM intervention concentration,, and 20 nmol/L ERL intervention concentration). All the cells from each treatment group were cultured for 24 hours and collected. Apoptosis of cells was examined by Annexin-V APC/7 AAD method. The expression of p53 gene in the cells of each treatment group was detected by real-time fluorescent quantitative PCR. The expressions of p53 and BAX of the cells of all the groups were detected by Western Blot, and compared with those of total proteins. Results: The apoptotic rate of PANC-1 in the pancreatic cancer cells of the combined group was higher than that in the control group, ERL group and GEM group(P<0.05). The expression of p53 gene in PANC-1 cells decreased more obviously in ERL group, GEM group and the combined group than in the control group(P<0.05). The expression of p53 decreased and its expression of BAX increased in the combined group more obviously than in the control, ERL and GEM groups(P<0.05). At the same time, the expression of p53 in pancreatic cancer cell line PANC-1 in the combined group was lower than that in ERL and GEM groups(P<0.05), and its expression of BAX was higher than that ERL and GEM groups(P<0.05). Conclusion: The therapy of GEM combined with ERL may play a better role in promoting tumor apoptosis by inducing p53 signaling pathway, down-regulating mutant p53, and inducing and up-regulating the expression of BAX.

关键词(KeyWords)： 胰腺肿瘤;细胞凋亡;厄洛替尼;吉西他滨;联合用药;p53蛋白
pancreatic cancer;apoptosis;erlotinib;gemcitabine;combination therapy;p53 protein

Abstract:

Keywords:

基金项目(Foundation): 贵州医科大学2018年度学术新苗培养及创新探索专项项目[黔科合平台人才(2018)5779-31]

作者(Authors): 黄欣昊;柳千帆;宋春灼;朱海涛;
HUANG Xinhao;LIU Qianfan;SONG Chunzuo;ZHU Haitao;Department of Clinical Medicine, Guizhou Medical University;Clinical Research Center of the Affiliated Hospital of Guizhou Medical University;Department of Hepatobiliary Surgery, The Affiliated Hospital of Guizhou Medical University;

DOI: 10.19367/j.cnki.1000-2707.2019.10.011

参考文献(References)：

• [1] RYAN D P,HONG T S,BARDEESY N.Pancreatic adenocarcinoma[J].N Engl J Med,2014,371(11):1039-1049.
• [2] VINCENT A,HERMAN J,SCHULICK R,et al.Pancreatic cancer[J].The Lancet,2011,378(9791):607-620.
• [3] OETTLE H,LEHMANN T.Gemcitabine-resistant pancreatic cancer:a second-line option[J].The Lancet,2016,387(10018):507-508.
• [4] SIEGEL R L,MILLER K D,JEMAL A.Cancer statistics,2017[J].CA Cancer J Clin,2017,67(1):7-30.
• [5] SIEGEL R L,MILLER K D,JEMAL A.Cancer statistics,2018[J].CA Cancer J Clin,2018,68(1):7-30.
• [6] MANOJ A,IVAR P,GLADHAU G.Pancreatic cancer chemoresistance to gemcitabine [J].Cancers,2017,9(11):157-169.
• [7] THIERRY C,BACHET J B,AHMET A ,et al.Current standards and new innovative approaches for treatment of pancreatic cancer [J].Science Direct,2016,57:10-22.
• [8] HIDALGO M.Pancreatic cancer[J].The New England Journal of Medicine,2010,362:1605-1617.
• [9] WANG Y N ,LEE H H ,CHOU C K,et al.Angiogenin/ribonuclease 5 is an EGFR ligand and a serum biomarker for erlotinib sensitivity in pancreatic cancer [J].Cancer Cell,2018,33(4):752-769.
• [10]SANGJIN S,CHAN M P,HANBYEOL K,et al.Erlotinib plus gemcitabine versusgemcitabine for pancreatic cancer:real-world analysis of korean national database[J].BMC Cancer,2016,16:443-449.
• [11]MIYABAYASHI K,IJICHI H,MOHRI D,et al.Erlotinib prolongs survival in pancreatic cancer by blocking gemcitabine-induced MAPK signals[J].Cancer Res,2013,73(7):2221-2234.
• [12]CHEN L,ZHOU D,LIU Z,et al.Combination of gemcitabine and erlotinib inhibits recurrent pancreatic cancer growth in mice via the JAK-STAT pathway[J].Oncol Rep,2018,39(3):1081-1089.
• [13]SUN H,MA H,HONG G,et al.Survival improvement in patients with pancreatic cancer by decade:a period analysis of the SEER database,1981-2010[J].Sci Rep,2014,4:6747-6757.
• [14]SOUSA C L,MONTEIRO G.Gemcitabine:metabolism and molecular mechanisms of action,sensitivity and chemoresistance in pancreatic cancer[J].Eur J Pharmacol,2014,741:8-16.
• [15]KULKE M H,BLASZKOWSKY L S,RYAN D P,et al.Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer journal of clinical oncology [J].The Official Journal Of the American Society of Clinical Oncology,2007,25(30):4787-4792.
• [16]PING W,ZHI X W.Epidermal growth factor receptor cell proliferation signaling pathways[J].Cancers,2017,9(5):52-96.
• [17]MENG G,GUOPEI L,CHEN L,et al.The prognostic and predictive role of epidermal growth factor receptor in surgical resected pancreatic cancer[J].International Journal of Molecular Sciences,2016,17(7):1090-1102.
• [18]IBRAHIM H S,CHRISTINE A I,EILEEN M O.Molecular signature of pancreatic adenocarcinoma:an insight from genotype to phenotype and challenges for targeted therapy [J].Expert Opinion on Therapeutic Targets,2016,20(3):341-359.
• [19]STATHIS,A,MOOR E.Advanced pancreatic carcinoma:current treatment and future challenges[J].Nature Reviews,2010,7:163-172.
• [20]LU L,ZENG J.Evaluation of k-ras and p53 expression in pancreatic adenocarcinoma using the cancer genome atlas[J].Plos One,2017,12(7):1-9.
• [21]李大虎,张令强,贺福初.突变体p53研究进展[J].遗传,2008,30(6):697-703.
• [22]王焕彬,许杰.恶性肿瘤复发与 p53 热点突变体的相关性研究[J].上海交通大学学报(医学版),2016,36(8):1121-1125.
• [23]刘同阳,郭海强,朱美妍,等.突变型p53与其合成致死基因的研究进展[J].遗传,2015,37(4):321-326.
• [24]MELLO S S,VALENTE L J,RAJ N,et al.A p53 super-tumor suppressor reveals a tumor suppressive p53-Ptpn14-Yap axis in pancreatic[J].Cancer Cell,2017,32(4):460-473.
• [25]AHMAD A,CHEN Y J,WANG W H,et al.Novel histone deacetyla se inhibitor AR-42 exhibits antitumor activity in pancreatic cancer cells by affecting multiple biochemical pathways[J].Plos One,2017,12(8):1-18.
• [26]DENIS E R,THOMAS P G,ANDREA L,et al.Direct activation of BAX by BTSA1 overcomes apoptosis resistance in acute myeloid leukemia [J].Cancer Cell,2017,32(4):490-505.
• [27]CHIN H S,LI M X,TAN I L,et al.VDAC2 enables BAX to mediate apoptosis and limit tumor development[J].Nat Commun,2018,9(1):4976-4988.
• [28]王江,魏晓丽,张爱华,等.Bax/BaK蛋白在凋亡通路中的调控与激活机制[J].生命的化学,2017,37(6):952-957.

文章评论(Comment)：